Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MB-CART19.1 in Patients With Relapsed/Refractory CD19-positive B Cell Acute Lymphoblastic Leukemia: A Feasibility Study

NCT07371403 is registered in ClinicalTrials.gov with King Hussein Cancer Center as lead sponsor.

NCT NCT07371403
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07371403 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MB-CART19.1 in Patients With Relapsed/Refractory CD19-positive B Cell Acute Lymphoblastic Leukemia: A Feasibility Study
Lead sponsor
King Hussein Cancer Center
Phase
Not applicable
Overall status
Recruiting
Start date
February 20, 2026
Completion date
January 31, 2029
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, acute lymphoblastic leukemia not having achieved remission, acute lymphoblastic leukemia recurrent, acute lymphoblastic leukemia refractory, acute lymphoblastic leukemia with failed remission